← Search & browse all drugs

ambroxol

R05CB06

Forms & Strengths

Tablet: 30 mg
Syrup: 15 mg/5 mL, 30 mg/5 mL
Solution for inhalation/drops: 7.5 mg/mL
Slow-release capsule: 75 mg
Ampoules for injection: 15 mg/2 mL

Adult Dosing

Tablet/Syrup: 30 mg to 60 mg orally three times daily
Slow-release capsule: 75 mg orally once daily
Injection: 15 mg intravenously or intramuscularly two to three times daily in severe cases

Pediatric Dosing

Under 2 years: 7.5 mg orally twice daily
2 to 5 years: 7.5 mg orally three times daily
6 to 12 years: 15 mg orally two to three times daily
Adolescents >12 years: Same as adult dosing

Indications

Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport

Mechanism of Action

Acts as a mucolytic agent, stimulating the serous cells of the bronchial glands to increase mucus production and decrease viscosity
Enhances ciliary activity to promote mucociliary clearance
Stimulates the synthesis and secretion of pulmonary surfactant

Contraindications

Hypersensitivity to ambroxol or bromhexine
Rare hereditary conditions that may be incompatible with an excipient
Severe renal or hepatic impairment (use with caution)

Adverse Reactions

Gastrointestinal: nausea, vomiting, dyspepsia, abdominal pain, diarrhea
Hypersensitivity: rash, urticaria, angioedema, anaphylactic reactions
Respiratory: rhinorrhea, dry mouth and airways
Skin: severe cutaneous adverse reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (very rare)

Drug Interactions

Antibiotics: increases concentrations of antibiotics such as amoxicillin, cefuroxime, and erythromycin in bronchopulmonary secretions and sputum
Antitussives: concurrent administration with cough suppressants (e.g., codeine) may cause dangerous mucus accumulation due to suppressed cough reflex

Curated Content: Needs Vetting Before Put to Clinical Use